Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort

Sheetal Hardikar, Lynn Onstad, Xiaoling Song, Angela M. Wilson, Thomas J. Montine, Mario Kratz, Garnet L. Anderson, Patricia L. Blount, Brian J. Reid, Emily White and Thomas L. Vaughan
Sheetal Hardikar
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2Department of Epidemiology, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shardika@fhcrc.org
Lynn Onstad
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoling Song
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela M. Wilson
3Department of Pathology, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Montine
3Department of Pathology, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Kratz
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2Department of Epidemiology, University of Washington, Seattle, Washington.
4Department of Medicine, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garnet L. Anderson
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
5Department of Biostatistics, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia L. Blount
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
4Department of Medicine, University of Washington, Seattle, Washington.
6Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Reid
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
4Department of Medicine, University of Washington, Seattle, Washington.
6Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
7Department of Genome Sciences, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily White
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2Department of Epidemiology, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas L. Vaughan
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2Department of Epidemiology, University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-14-0384 Published November 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Persons with Barrett's esophagus experience increased risk of esophageal adenocarcinoma. Prediagnostic inflammation markers predict several cancers, but their role in predicting esophageal adenocarcinoma is unknown.

Methods: We investigated whether biomarkers of inflammation [C-reactive protein (CRP), interleukin-6 (IL6), soluble tumor necrosis factor (sTNF) receptors I and II], and of oxidative stress (F2-isoprostanes) predicted progression to esophageal adenocarcinoma in a prospective cohort of 397 patients with Barrett's esophagus, 45 of whom developed esophageal adenocarcinoma. Biomarkers were measured in stored plasma samples from two time points during follow-up, the mean of which served as the primary predictor. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression.

Results: CRP level above the median was associated with an 80% increased risk of esophageal adenocarcinoma. The HR and 95% CI adjusted for age, gender, and further adjusted for waist–hip ratio and smoking were 1.98 (1.05–3.73) and 1.77 (0.93–3.37), respectively, with Ptrend for continuous CRP = 0.04. Persons with IL6 levels above the median also had almost 2-fold increased risk [HR and 95% CI adjusted for age and gender, and further adjusted for waist–hip ratio and smoking were 1.95 (1.03–3.72) and 1.79 (0.93–3.43), respectively, but no evidence of a trend was observed]. Concentrations of TNF receptors and F2-isoprostanes were not associated with esophageal adenocarcinoma risk.

Conclusions: Further research is needed to evaluate the role of inflammation and associated markers in esophageal adenocarcinoma development in persons with Barrett's esophagus.

Impact: This prospective study suggests that inflammation markers, particularly CRP and IL6, may help identify persons at higher risk of progression to esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 23(11); 2393–403. ©2014 AACR.

Introduction

Chronic inflammation has been hypothesized to play an important role in the pathogenesis of cancers of the lung, colon, and other organs (1–5). Similarly, oxidative stress has been implicated in cancers of the lung (6), breast (7), and prostate (8). Inflammation may contribute to cancer development through multiple mechanisms, including DNA damage, angiogenesis, promotion of cellular proliferation, and inhibition of apoptosis (1). Inflammatory processes also lead to generation of reactive oxygen species (ROS), which may cause inactivating mutations in tumor-suppressor genes or posttranslational modifications in DNA repair proteins, thus promoting carcinogenesis (1, 5).

In the gastrointestinal tract, several chronic inflammatory conditions have been associated with cancer: inflammatory bowel disease with colorectal cancer (9), hepatitis B and C with liver cancer (10), and chronic Helicobacter pylori gastritis with gastric cancer (11). Similarly, inflammatory conditions of the esophagus, namely reflux esophagitis and Barrett's esophagus, are implicated in the development of esophageal adenocarcinoma, with Barrett's esophagus widely considered to be a premalignant lesion for esophageal adenocarcinoma (12–14). The inflammatory link with esophageal adenocarcinoma is further strengthened by the observation that regular use of nonsteroidal anti-inflammatory drugs (NSAID) and aspirin is associated with decreased risk (15–17).

The incidence of esophageal adenocarcinoma has increased dramatically over the past four decades (18). Although the relative risk of esophageal adenocarcinoma is at least 30-times higher in individuals with Barrett's esophagus compared with those without (19), absolute risk of progression is relatively low (0.12%–0.6% per year; refs. 20–22), and it is not yet clear which persons with Barrett's esophagus are most likely to develop esophageal adenocarcinoma, or whether lifestyle modifications might help prevent esophageal adenocarcinoma within this higher-risk population. Previous studies identified obesity, cigarette smoking, gastroesophageal reflux, and diet as potential modifiable risk factors for esophageal adenocarcinoma (14, 23). However, the roles of inflammation and oxidative stress as potentially modifiable risk factors or predictors for esophageal adenocarcinoma have not been studied directly. In this report, we assess the association between markers of systemic inflammation and oxidative stress and the subsequent risk of esophageal adenocarcinoma in a well-characterized Barrett's esophagus cohort followed for up to 14.5 years.

Materials and Methods

Study population, follow-up, and cancer ascertainment

The Seattle Barrett's Esophagus Study (SBES), is a prospective cohort study aimed at understanding the risk factors and mechanisms underlying neoplastic progression to esophageal adenocarcinoma among persons with Barrett's esophagus. The SBES cohort is one of the largest and longest-running well-characterized cohorts of persons with Barrett's esophagus in the world. Details of the cohort have been described previously (23, 24). The study involves periodic endoscopic surveillance for all participants, with multiple biopsies of the Barrett's segment. The current report includes the 427 SBES participants with Barrett's esophagus and no history of esophageal cancer enrolled between February 1995 and September 2009, of whom 411 (96.3%) had at least one follow-up visit. At their baseline visit, participants underwent an extensive personal interview, anthropometric assessment, endoscopy with biopsy, and blood draw. At subsequent follow-up visits, baseline information was updated, additional blood was collected, and a repeat endoscopy with biopsies was performed (12, 13, 25). Specimens were fixed, processed, and interpreted by a single pathologist blinded to the participants' exposure status (12). Individuals were classified as having Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, or esophageal adenocarcinoma based on their most severe histologic diagnosis. Participants with high-grade dysplasia at their initial endoscopy (80 of 411 participants; 19.46%) were endoscoped twice more within 5 months to detect any occult cancers missed at baseline. Of the 411 SBES participants eligible for analyses, 14 individuals had less than 5 months of follow-up and 11 of these developed cancer. Because of an a priori concern that cancers diagnosed during this early period of intensive search for occult malignancies may have been present at baseline, these 14 individuals were excluded from the primary statistical analyses. Esophageal adenocarcinoma was defined as invasion of neoplastic epithelium beyond the basement membrane of the esophageal mucosa into the surrounding lamina propria, muscularis mucosa, or submucosa (12). This study was approved by the Institutional Review Boards at the University of Washington and Fred Hutchinson Cancer Research Center.

Inflammation marker measurements

Fasting blood samples were collected, processed (most within 2 hours after collection), and stored at −80°C until analysis. Potential inflammation markers were identified from the literature, and selected for use in this study based on the sensitivity and accuracy of available assays, giving consideration to their cost. Plasma levels of C-reactive protein (CRP), IL6, and soluble tumor necrosis factor (sTNF) receptors were measured using samples from the first two available time points (baseline and first follow-up for most participants, mean duration between two samples, 1.8 years). F2-isoprostanes were measured at a single time point (earliest available, baseline for most). Intra- and interbatch coefficients of variation (CV) were calculated using blinded pooled plasma samples included as quality controls within each batch. Intraclass correlation coefficients (ICC) and 95% confidence intervals (CI) were calculated using the two cytokine measurements per participant, as described previously (26).

Briefly, CRP concentrations were measured in never-thawed plasma samples with a high-sensitivity assay using immunonephelometry [Dade Behring Inc; Interbatch CV; 2.9%; ICC (95% CI), 54.9% (47.4–62.5)]. The assay detectable limit was 0.2 mg/L; a value of 0.1 mg/L was assigned to all participants with CRP concentrations below the detection limit (<1% samples). IL6 was assayed in never-thawed plasma samples using the Quantikine HS human IL6 Elisa kit [R&D Systems Inc; HS600B; interbatch CV, 4.4%; intrabatch CV, 4.1%; ICC (95% CI), 56.4% (49.4–63.4)]. Samples were run in duplicate with a median duplicate CV of 2.7%; samples with CVs greater than 12% were rerun and the repeat measurements were used for analysis. sTNFR-I and sTNFR-II were measured on previously thawed and refrozen plasma samples using the MILLIPLEX MAP Human Soluble Cytokine Receptor Panel [Millipore; HSCR-32K; sTNFR-I: interbatch CV, 8.9%; intrabatch CV, 5.9%; ICC (95% CI), 89.2% (87.2–91.3); sTNFR-II: interbatch CV, 6.1%; intrabatch CV, 2.4%, ICC (95% CI), 84.9% (82.1–87.8)]. Samples were run in duplicate with a median duplicate CV of 4.1% and 3.4% for sTNFRI and sTNFRII, respectively. F2-isoprostanes were estimated in never-thawed plasma samples using gas chromatography/negative ion chemical ionization mass spectrometry (GC/NICI-MS) as described previously (6890N Agilent gas chromatograph, 5973 quadruple mass spectrometer; refs. 27, 28). This assay had a precision of ±3%, accuracy of 97%, and a detection limit of 20 pg/mL.

Other covariates

Detailed information on medical, family, and medication histories, as well as on lifestyle exposures such as tobacco use, were collected in a personal interview conducted by trained staff. Anthropometric measurements, including height, weight, and waist, hip, thigh, and abdominal circumferences, were determined using an established protocol (23) and were used to calculate waist–hip ratio (WHR) and body mass index [BMI; weight (kg)/height (m)2], which was categorized as normal (<25 kg/m2), overweight (≥25 and <30 kg/m2), and obese (≥30 kg/m2). Cumulative pack-years of smoking were computed using the number of packs smoked per day and the number of years smoked.

Statistical analysis

We estimated the associations between markers of inflammation and oxidative stress and the risk of esophageal adenocarcinoma by calculating hazard ratios (HR) and 95% CIs using separate Cox models for each biomarker. As we dropped individuals with less than 5 months of follow-up from our primary statistical analyses, time at risk to development of esophageal adenocarcinoma began 5 months postbaseline for all participants. For participants with inflammation marker measurements available at two time points during the follow-up, the mean of the two measures was used as the primary predictor; otherwise, the lone measure was used. If the outcome occurred during the same visit as a biomarker measurement, only the first measurement was used for risk prediction. A priori, we decided to exclude CRP values more than 10 mg/L from analyses due to the possibility that such elevated concentrations may be the result of acute rather than chronic inflammation (29, 30). Eight participants had both their CRP measures more than 10 mg/L and, hence, were dropped from all CRP-related analyses. Biomarker concentrations were tested for associations with esophageal adenocarcinoma risk using three models: unadjusted; age- and gender-adjusted; and adjusted for obesity, smoking, and NSAID use in addition to age and gender. These specific confounders were selected on the basis of the previously established risk factors of esophageal adenocarcinoma (increasing age, male gender, smoking, higher WHR, and use of NSAIDs; refs. 14, 23) determined a priori, and their correlations with the biomarkers, based on Pearson correlation coefficients. Although it is more conventional to adjust for the effects of obesity by adjusting for BMI, we chose to adjust for WHR (a measure of central adiposity) in the current analyses as there is good evidence that WHR is more strongly associated with Barrett's esophagus as compared with BMI (31). Analyses were conducted on quartiles of the various biomarkers, as well as by median level. Analyses were repeated restricted to males (number of females was too small for meaningful results). Tests for trend were based on the likelihood-ratio test associated with addition of the biomarker being evaluated in its continuous form. A two-sided P value less than 0.05 was considered statistically significant. The assumption of proportional hazards over time was tested. All analyses were performed using STATA statistical package, release 12 (StataCorp).

Results

Participant characteristics for the 411 individuals eligible for current analyses are presented in Table 1. The majority of the cohort was Caucasian (96.6%) and male (81.3%), with a mean age of 61.2 years. More than 39% of the participants were obese, 64% were current or former smokers, 81.5% reported regular alcohol use in their lifetime, and 60.6% had regularly taken NSAIDs at some point in their life. The mean WHR for the entire cohort was 0.95 (males, 0.96; females, 0.87).

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of all participants, males and females, in the SBES cohort (n = 411)

The medians and interquartile ranges for the various biomarkers overall and by gender are presented in Table 2 (distributions by gender were based on sex-specific quartiles). Overall, the distributions of the various biomarkers evaluated in this study are comparable with other studies of older populations and obese individuals (32–34).

View this table:
  • View inline
  • View popup
Table 2.

Distribution of mean biomarker levels overall and by gender in the SBES cohort (n = 411)

The Pearson correlation coefficients between the biomarkers and risk factors for esophageal adenocarcinoma are shown in Table 3. The correlations between the biomarkers themselves were small to moderate (0.12–0.63), and were statistically significant (except IL6 and F2-isoprostanes). Therefore, these biomarkers were evaluated in separate models with respect to their esophageal adenocarcinoma risk. Most of the biomarkers were significantly correlated with age, WHR, and cigarette pack-years, suggesting that these factors might confound the biomarker–esophageal adenocarcinoma associations.

View this table:
  • View inline
  • View popup
Table 3.

Relationship between the biomarkers and correlates of esophageal adenocarcinoma (n = 411)

Table 4 presents the HRs and 95% CIs for developing esophageal adenocarcinoma according to biomarker levels among the 397 participants in the primary analysis. They were followed for a median of 6.14 years (31,677 person-months), and 45 developed cancer. Plasma samples were not available for 3 individuals. For analyses involving CRP, we omitted 8 participants for whom all available CRP values were more than 10 mg/L (2 out of these 8 developed esophageal adenocarcinoma; total 43 cancers in analyses based on CRP). Ultimately, analyses were conducted on 394 participants for IL6 and sTNF receptors, 386 participants for CRP, and 377 participants for F2-isoprostanes.

View this table:
  • View inline
  • View popup
Table 4.

HRs and 95% CI for esophageal adenocarcinoma associated with markers of systemic inflammation (CRP, IL6, sTNF-RI, and sTNF-RII) and markers of oxidative stress (F2-isoprostanes) in the SBES cohort (n = 397)

Mean CRP levels above the median of 1.9 mg/L were associated with a 2-fold increased esophageal adenocarcinoma risk compared with those with values below the median, after adjustment for age and gender (HR, 1.98; 95% CI, 1.05–3.73, Ptrend for continuous CRP = 0.01). Further adjustment for WHR, smoking, and NSAIDs attenuated the association somewhat (HR, 1.77; 95% CI, 0.93–3.37; Ptrend for continuous CRP = 0.04). Analyses limited to men revealed slightly stronger associations with CRP.

Participants with average IL6 levels above the median had a 2-fold increased risk for esophageal adenocarcinoma (HR, 1.95; 95% CI, 1.03–3.72) but no evidence of a trend was observed (Ptrend = 0.94). The increase in risk was more pronounced among males, with an almost 3-fold increased risk (HR, 2.85; 95% CI, 1.38–5.92) after adjustment for age and gender. Overall as well as in the subgroup analysis for males, additional adjustment for obesity, smoking, and NSAIDs had little effect. No evidence of an association between sTNF-RI and esophageal adenocarcinoma risk was observed. For sTNF-RII, although univariate analyses overall and among males revealed statistically significant associations, adjustment for confounders attenuated the association substantially such that it was no longer statistically significant. Circulating levels of F2-isoprostanes were not associated with increased risk of esophageal adenocarcinoma in this cohort.

To evaluate if the significant associations observed with CRP and IL6 were more pronounced within the first few years of follow-up, we conducted subanalyses restricting the follow-up time to 3 and 5 years from baseline (Fig. 1). The associations with CRP were stronger and the statistical trends more pronounced (Ptrend for continuous CRP = 0.02 in a fully adjusted model) with the restricted 5-year follow-up. The associations with IL6 did not alter much after restricting the follow-up to 3 or 5 years. We repeated our main analyses after adding the 14 individuals with less than 5 months of follow-up that we had initially excluded, with no important differences found (data not shown). To examine whether prolonged storage of biologic samples affected our results, we also conducted a sensitivity analysis restricted to only those individuals whose biologic samples had been stored for 10 years or less (mean storage time for the earlier of the two samples from an individual was 12 years). We found that although the results for CRP were slightly stronger and those for IL6 were weaker as compared with the main statistical analysis, the overall conclusions remained the same (data not shown). As IL6 may be produced by the metaplastic epithelium (35), we also investigated the effect of adjustment for Barrett's esophagus segment length in models involving IL6 and found that the point estimate was reduced by a small amount—from 1.79 to 1.60.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Relationship between association of esophageal adenocarcinoma (EA) with plasma CRP (A) and IL6 (B) with follow-up restricted to 3 and 5 years from baseline. All models are adjusted for confounding effects of age, gender, smoking (pack-years), and obesity (WHR).

We also computed an “inflammation score” based on the quartile categories for various biomarkers such that individuals in the lowest quartile for a biomarker received a score of 0 and those in the highest quartile received a score of 3. Using the summed combined score as the primary predictor, we found that esophageal adenocarcinoma risk nonsignificantly increased by 2% per unit increase in the score in adjusted models (data not shown).

Discussion

In this prospective study, we observed that elevated prediagnostic blood concentrations of CRP and possibly IL6 are associated with subsequent increased incidence of esophageal adenocarcinoma among persons with Barrett's esophagus. Plasma levels of sTNF receptors or isoprostanes were not statistically significantly associated with esophageal adenocarcinoma risk.

The role of inflammation and resulting oxidative stress in the development of cancer has been the focus of extensive research (3, 36, 37). More recently, inflammation markers, particularly CRP and IL6, have been reported to be associated with all cancers in prospective and nested case–control studies. In a prospective Danish cohort of 10,000 individuals, the risk for any cancer associated with CRP levels more than 3 mg/L was 1.3 (95% CI, 1.0–1.6; ref. 38); a similar 1.2-fold (95% CI, 1.10–1.32) increased risk for any cancer with increasing CRP was observed in a Greek cohort (39). In another prospective study involving the Health Aging and Body Composition cohort, risk for all cancers increased with higher levels of CRP, IL6, and TNFα (40). In studies looking at individual cancer sites, the evidence for a possible role of chronic inflammation is the strongest for colon cancer (38, 40–43). Elevated levels of inflammatory markers have also been shown to be associated with cancers of the lung (38–40, 44, 45), breast (39, 40, 45) and ovary (46). Oxidative stress markers such as F2-isoprostanes and oxodeoxyguanosine have been shown to be associated with cancers of colon, lung, prostate, and breast (6–8, 47, 48).

Our study adds to the accumulating evidence for a key role of inflammation in esophageal adenocarcinoma development, even among persons already diagnosed with Barrett's esophagus. Exposure of the esophageal epithelium to bile salts and acid resulting from gastroesophageal reflux can cause chronic inflammation of the lower esophagus and result in increased release of proinflammatory mediators (49–51), which may, in turn, cause DNA damage and promote progression (1, 49). In support of this hypothesis, an experimental study showed that Barrett's esophagus tissue secretes significant amounts of IL6 resulting in an increased expression of STAT3 transcription factor that may lead to neoplastic conversion (35). In another study, the levels of ROS were higher in biopsy specimens from patients with Barrett's esophagus than those from controls, suggesting that they play a role in the tissue injury associated with Barrett's esophagus (52). In our own cohort, we have previously shown that leukocyte telomere length, a measure of person's long-term inflammation level and oxidative damage (53), was associated with more than a 3-fold increased risk of esophageal adenocarcinoma (Ptrend = 0.009; ref. 54), and that anti-inflammatory drugs such as NSAIDs reduce the risk of esophageal adenocarcinoma even among those with dysplastic changes in their Barrett's segment (15). Here, we show a link between prediagnostic concentrations of inflammation markers and esophageal adenocarcinoma among patients with Barrett's esophagus, suggesting that pathways involving inflammatory biomarkers present prevention targets.

Blood-based markers of chronic systemic inflammation may also reflect systemic response to other exposures that predispose to esophageal cancer, such as obesity. Inflammatory cytokines, including IL6 and TNF-α, have been observed to be systematically elevated in obesity (55, 56), and dietary intervention studies have shown that weight loss reduces CRP levels among obese individuals (57). We have previously reported a modest increase in esophageal adenocarcinoma risk associated with measures of central adiposity (23). Results from the present study indicate that CRP and IL6 may be predictive in esophageal adenocarcinoma development even after adjustment for confounding effects of obesity in patients with Barrett's esophagus. Taken together, these results suggest that inflammation markers may mediate the association of obesity with esophageal adenocarcinoma, but they also have some independent effect on esophageal adenocarcinoma development beyond their effect through obesity.

This study has several strengths. Its prospective design allowed for measurement of multiple markers of inflammation and oxidative stress before the development of cancer, minimizing the possibility of reverse causality. For the majority of the biomarkers, we also were able to assess plasma levels at two time points during follow-up, thus reducing random measurement error and the potential for regression dilution bias (58, 59). In addition, measuring the biomarkers at two time points enabled us to improve on the ICCs reported earlier (Materials and Methods) by capturing some of the intraperson variation. For example, the ICC of 0.55 for CRP that we reported earlier is actually improved to 0.71 just by averaging over two CRP measurements (60). We also blinded the laboratory personnel to participants' disease status. Comprehensive measurement of covariates such as WHR and pack-years of smoking enabled us to limit confounding. We also carried out analyses restricting to the first 3 and 5 years of follow-up, so as to minimize the misclassification of inflammation marker status due to prolonged duration between measurement of inflammation markers and occurrence of esophageal adenocarcinoma events, and observed stronger associations and more pronounced trends.

Our study is limited by the relatively small number of incident esophageal adenocarcinoma cases, despite being one of the largest, well-characterized cohorts of patients with Barrett's esophagus reported in the literature. Although we controlled for potential confounding effects of smoking, obesity, and NSAID use in multivariable analyses, we cannot exclude the possibility of residual confounding by measured and unmeasured risk factors. In particular, we did not collect data on Helicobacter pylori status, which has been shown to be inversely related to esophageal adenocarcinoma risk (61, 62), while at the same time being associated with systemic inflammation (63) such that H. pylori eradication therapies reduce the blood levels of proinflammatory cytokines, including CRP (64). We did not adjust for confounding by the length of Barrett's segment in our analysis. Although a recent study showed that presence of long-segment Barrett's esophagus carried a 7-fold increased risk of progression to esophageal adenocarcinoma (65), Barrett's esophagus segment length is only modestly associated with the risk of esophageal adenocarcinoma in our cohort (66). We attempted to limit measurement error by using high sensitivity and reliable assays for biomarker measurement. However, we cannot exclude the possibility of errors in biomarker measurement resulting from degradation of biologic samples during storage. Finally, as the study cohort represents a specialty clinic, results presented in the current report should be cautiously interpreted in terms of their generalizability to the general population.

In conclusion, our results indicate that systemic levels of CRP and, to some extent, IL6 are associated with progression to esophageal adenocarcinoma in persons with Barrett's esophagus. Soluble TNF receptors and F2-isoprostanes were not found to be associated with increased esophageal adenocarcinoma risk. Our findings with CRP and IL6 are consistent with the literature that supports the role of chronic inflammation in the development of cancer, and esophageal adenocarcinoma in particular. Additional analyses involving further follow-up of this and other cohorts are needed to confirm these findings, as well as to evaluate the utility of biomarker assessment in clinical prediction and risk stratification of esophageal adenocarcinoma.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Disclaimer

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the article.

Authors' Contributions

Conception and design: S. Hardikar, M. Kratz, B.J. Reid, T.L. Vaughan

Development of methodology: S. Hardikar, T.J. Montine, T.L. Vaughan

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Hardikar, X. Song, A.M. Wilson, T.J. Montine, P.L. Blount, B.J. Reid, T.L. Vaughan

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Hardikar, M. Kratz, G.L. Anderson, B.J. Reid, E. White, T.L. Vaughan

Writing, review, and/or revision of the manuscript: S. Hardikar, L. Onstad, X. Song, T.J. Montine, M. Kratz, G.L. Anderson, P.L. Blount, B.J. Reid, E. White, T.L. Vaughan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Hardikar, L. Onstad, X. Song

Study supervision: X. Song, T.L. Vaughan

Grant Support

This work was supported by NIH grants P01CA091955 (to B.J. Reid), K05CA124911 (to T.L. Vaughan), and R25CA094880 (to E. White).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank Tricia Christopherson for project management; Terri Watson for database management; and Christine Karlsen for coordination of patient care.

  • Received April 15, 2014.
  • Revision received June 25, 2014.
  • Accepted July 17, 2014.
  • ©2014 American Association for Cancer Research.

References

  1. 1.↵
    1. Coussens LM,
    2. Werb Z
    . Inflammation and cancer. Nature 2002;420:860–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Balkwill F,
    2. Mantovani A
    . Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Federico A,
    2. Morgillo F,
    3. Tuccillo C,
    4. Ciardiello F,
    5. Loguercio C
    . Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121:2381–6.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Klaunig JE,
    2. Wang Z,
    3. Pu X,
    4. Zhou S
    . Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 2011;254:86–99.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Hussain SP,
    2. Harris CC
    . Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373–80.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Epplein M,
    2. Franke AA,
    3. Cooney RV,
    4. Morris JS,
    5. Wilkens LR,
    6. Goodman MT,
    7. et al.
    Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2009;18:1962–70.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Rossner P Jr.,
    2. Gammon MD,
    3. Terry MB,
    4. Agrawal M,
    5. Zhang FF,
    6. Teitelbaum SL,
    7. et al.
    Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:639–44.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Gill JK,
    2. Franke AA,
    3. Steven Morris J,
    4. Cooney RV,
    5. Wilkens LR,
    6. Le Marchand L,
    7. et al.
    Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control 2009;20:1161–71.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Triantafillidis JK,
    2. Nasioulas G,
    3. Kosmidis PA
    . Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009;29:2727–37.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Szabo G,
    2. Lippai D
    . Molecular hepatic carcinogenesis: impact of inflammation. Dig Dis 2012;30:243–8.
    OpenUrlPubMed
  11. 11.↵
    1. Bornschein J,
    2. Selgrad M,
    3. Warnecke M,
    4. Kuester D,
    5. Wex T,
    6. Malfertheiner P
    . H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci 2010;55:3124–31.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Reid BJ,
    2. Levine DS,
    3. Longton G,
    4. Blount PL,
    5. Rabinovitch PS
    . Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669–76.
    OpenUrlPubMed
  13. 13.↵
    1. Reid BJ,
    2. Blount PL,
    3. Rubin CE,
    4. Levine DS,
    5. Haggitt RC,
    6. Rabinovitch PS
    . Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212–9.
    OpenUrlPubMed
  14. 14.↵
    1. Reid BJ,
    2. Li X,
    3. Galipeau PC,
    4. Vaughan TL
    . Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87–101.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Vaughan TL,
    2. Dong LM,
    3. Blount PL,
    4. Ayub K,
    5. Odze RD,
    6. Sanchez CA,
    7. et al.
    Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945–52.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Liao LM,
    2. Vaughan TL,
    3. Corley DA,
    4. Cook MB,
    5. Casson AG,
    6. Kamangar F,
    7. et al.
    Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012;142:442–52.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bosetti C,
    2. Rosato V,
    3. Gallus S,
    4. Cuzick J,
    5. La Vecchia C
    . Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012;23:1403–15.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Cook MB,
    2. Chow WH,
    3. Devesa SS
    . Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer 2009;101:855–9.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Oh DS,
    2. Demeester SR
    . Pathophysiology and treatment of Barrett's esophagus. World J Gastroenterol 2010;16:3762–72.
    OpenUrlPubMed
  20. 20.↵
    1. Yousef F,
    2. Cardwell C,
    3. Cantwell MM,
    4. Galway K,
    5. Johnston BT,
    6. Murray L
    . The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237–49.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Bhat S,
    2. Coleman HG,
    3. Yousef F,
    4. Johnston BT,
    5. McManus DT,
    6. Gavin AT,
    7. et al.
    Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049–57.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Hvid-Jensen F,
    2. Pedersen L,
    3. Drewes AM,
    4. Sorensen HT,
    5. Funch-Jensen P
    . Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375–83.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Hardikar S,
    2. Onstad L,
    3. Blount PL,
    4. Odze RD,
    5. Reid BJ,
    6. Vaughan TL
    . The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS ONE 2013;8:e52192.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Galipeau PC,
    2. Li X,
    3. Blount PL,
    4. Maley CC,
    5. Sanchez CA,
    6. Odze RD,
    7. et al.
    NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007;4:e67.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Rabinovitch PS,
    2. Longton G,
    3. Blount PL,
    4. Levine DS,
    5. Reid BJ
    . Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071–83.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Hardikar S,
    2. Song X,
    3. Kratz M,
    4. Anderson GL,
    5. Blount PL,
    6. Reid BJ,
    7. et al.
    Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes Control 2014;25:969–76.
    OpenUrlPubMed
  27. 27.↵
    1. Milatovic D,
    2. Montine TJ,
    3. Aschner M
    . Measurement of isoprostanes as markers of oxidative stress. Methods Mol Biol 2011;758:195–204.
    OpenUrlPubMed
  28. 28.↵
    1. Milne GL,
    2. Yin H,
    3. Brooks JD,
    4. Sanchez S,
    5. Jackson Roberts L II.,
    6. Morrow JD
    . Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007;433:113–26.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Myers GL,
    2. Rifai N,
    3. Tracy RP,
    4. Roberts WL,
    5. Alexander RW,
    6. Biasucci LM,
    7. et al.
    CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the laboratory science discussion group. Circulation 2004;110:e545–9.
    OpenUrlFREE Full Text
  30. 30.↵
    1. Pearson TA,
    2. Mensah GA,
    3. Alexander RW,
    4. Anderson JL,
    5. Cannon RO III.,
    6. Criqui M,
    7. et al.
    Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
    OpenUrlFREE Full Text
  31. 31.↵
    1. Kubo A,
    2. Cook MB,
    3. Shaheen NJ,
    4. Vaughan TL,
    5. Whiteman DC,
    6. Murray L,
    7. et al.
    Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013;62:1684–91.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Colbert LH,
    2. Visser M,
    3. Simonsick EM,
    4. Tracy RP,
    5. Newman AB,
    6. Kritchevsky SB,
    7. et al.
    Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004;52:1098–104.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Hauner H,
    2. Bender M,
    3. Haastert B,
    4. Hube F
    . Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord 1998;22:1239–43.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Olszanecka-Glinianowicz M,
    2. Zahorska-Markiewicz B,
    3. Janowska J,
    4. Zurakowski A
    . Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-alpha and TNF soluble receptors in women with overweight and obesity. Metabolism 2004;53:1268–73.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Dvorakova K,
    2. Payne CM,
    3. Ramsey L,
    4. Holubec H,
    5. Sampliner R,
    6. Dominguez J,
    7. et al.
    Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004;10:2020–8.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Kundu JK,
    2. Surh YJ
    . Inflammation: gearing the journey to cancer. Mutat Res 2008;659:15–30.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Allavena P,
    2. Garlanda C,
    3. Borrello MG,
    4. Sica A,
    5. Mantovani A
    . Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008;18:3–10.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Allin KH,
    2. Bojesen SE,
    3. Nordestgaard BG
    . Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217–24.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Trichopoulos D,
    2. Psaltopoulou T,
    3. Orfanos P,
    4. Trichopoulou A,
    5. Boffetta P
    . Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381–4.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Il'yasova D,
    2. Colbert LH,
    3. Harris TB,
    4. Newman AB,
    5. Bauer DC,
    6. Satterfield S,
    7. et al.
    Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413–8.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Erlinger TP,
    2. Platz EA,
    3. Rifai N,
    4. Helzlsouer KJ
    . C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585–90.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Gunter MJ,
    2. Stolzenberg-Solomon R,
    3. Cross AJ,
    4. Leitzmann MF,
    5. Weinstein S,
    6. Wood RJ,
    7. et al.
    A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483–7.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Otani T,
    2. Iwasaki M,
    3. Sasazuki S,
    4. Inoue M,
    5. Tsugane S
    . Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006;15:690–5.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Pine SR,
    2. Mechanic LE,
    3. Enewold L,
    4. Chaturvedi AK,
    5. Katki HA,
    6. Zheng YL,
    7. et al.
    Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011;103:1112–22.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Siemes C,
    2. Visser LE,
    3. Coebergh JW,
    4. Splinter TA,
    5. Witteman JC,
    6. Uitterlinden AG,
    7. et al.
    C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216–22.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Poole EM,
    2. Lee IM,
    3. Ridker PM,
    4. Buring JE,
    5. Hankinson SE,
    6. Tworoger SS
    . A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor alpha receptor 2 levels and risk of ovarian cancer. Am J Epidemiol 2013;178:1256–64.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Babbs CF
    . Free radicals and the etiology of colon cancer. Free Radic Biol Med 1990;8:191–200.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Kong SY,
    2. Bostick RM,
    3. Flanders WD,
    4. McClellan WM,
    5. Thyagarajan B,
    6. Gross MD,
    7. et al.
    Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev 2014;23:545–54.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Abdel-Latif MM,
    2. Duggan S,
    3. Reynolds JV,
    4. Kelleher D
    . Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 2009;9:396–404.
    OpenUrlPubMed
  50. 50.↵
    1. Poehlmann A,
    2. Kuester D,
    3. Malfertheiner P,
    4. Guenther T,
    5. Roessner A
    . Inflammation and Barrett's carcinogenesis. Pathol Res Pract 2012;208:269–80.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Farhadi A,
    2. Fields J,
    3. Banan A,
    4. Keshavarzian A
    . Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am J Gastroenterol 2002;97:22–6.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Olyaee M,
    2. Sontag S,
    3. Salman W,
    4. Schnell T,
    5. Mobarhan S,
    6. Eiznhamer D,
    7. et al.
    Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut 1995;37:168–73.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Houben JM,
    2. Moonen HJ,
    3. van Schooten FJ,
    4. Hageman GJ
    . Telomere length assessment: biomarker of chronic oxidative stress? Free Radic Biol Med 2008;44:235–46.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Risques RA,
    2. Vaughan TL,
    3. Li X,
    4. Odze RD,
    5. Blount PL,
    6. Ayub K,
    7. et al.
    Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007;16:2649–55.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Yudkin JS
    . Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S25–8.
    OpenUrl
  56. 56.↵
    1. Yudkin JS,
    2. Stehouwer CD,
    3. Emeis JJ,
    4. Coppack SW
    . C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972–8.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Dietrich M,
    2. Jialal I
    . The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev 2005;63:22–8.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Berglund L
    . Regression dilution bias: tools for correction methods and sample size calculation. Ups J Med Sci 2012;117:279–83.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Clarke R,
    2. Shipley M,
    3. Lewington S,
    4. Youngman L,
    5. Collins R,
    6. Marmot M,
    7. et al.
    Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341–53.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. White E,
    2. Armstrong BK,
    3. Saracci R
    . Priciples of exposure measurement in epidemiology:collecting, evaluating, and improving measures of disease risk factors. Great Britain: Oxford University Press; 2008.
  61. 61.↵
    1. Chow WH,
    2. Blaser MJ,
    3. Blot WJ,
    4. Gammon MD,
    5. Vaughan TL,
    6. Risch HA,
    7. et al.
    An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588–90.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Islami F,
    2. Kamangar F
    . Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res 2008;1:329–38.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Jackson L,
    2. Britton J,
    3. Lewis SA,
    4. McKeever TM,
    5. Atherton J,
    6. Fullerton D,
    7. et al.
    A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 2009;14:108–13.
    OpenUrlPubMed
  64. 64.↵
    1. Kebapcilar L,
    2. Bilgir O,
    3. Cetinkaya E,
    4. Akyol M,
    5. Bilgir F,
    6. Bozkaya G
    . The effect of Helicobacter pylori eradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-a levels. Clinics 2010;65:799–802.
    OpenUrlPubMed
  65. 65.↵
    1. Coleman HG,
    2. Bhat SK,
    3. Murray LJ,
    4. McManus DT,
    5. O'Neill OM,
    6. Gavin AT,
    7. et al.
    Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk. Am J Gastroenterol 2014;109:527–34.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Rudolph RE,
    2. Vaughan TL,
    3. Storer BE,
    4. Haggitt RC,
    5. Rabinovitch PS,
    6. Levine DS,
    7. et al.
    Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612–20.
    OpenUrlPubMed
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 23 (11)
November 2014
Volume 23, Issue 11
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort
Sheetal Hardikar, Lynn Onstad, Xiaoling Song, Angela M. Wilson, Thomas J. Montine, Mario Kratz, Garnet L. Anderson, Patricia L. Blount, Brian J. Reid, Emily White and Thomas L. Vaughan
Cancer Epidemiol Biomarkers Prev November 1 2014 (23) (11) 2393-2403; DOI: 10.1158/1055-9965.EPI-14-0384

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort
Sheetal Hardikar, Lynn Onstad, Xiaoling Song, Angela M. Wilson, Thomas J. Montine, Mario Kratz, Garnet L. Anderson, Patricia L. Blount, Brian J. Reid, Emily White and Thomas L. Vaughan
Cancer Epidemiol Biomarkers Prev November 1 2014 (23) (11) 2393-2403; DOI: 10.1158/1055-9965.EPI-14-0384
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Disclaimer
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Gallstones and Gallbladder Cancer
  • Additive Effects of Aristolochic Acid and Arsenic in UTUC
  • Provider Lifestyle Discussions
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement